CoChat

Utility of a physiologically–based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug–drug–disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice

Grillo, Joseph A., Zhao, Ping, Bullock, Julie, Booth, Brian P., Lu, Min, Robie‐Suh, Kathy, Berglund, Eva Gil, Pang, K. Sandy, Rahman, Atiqur, Zhang, Lei, Lesko, Lawrence J., Huang, Shiew‐Mei · 2012 · Biopharmaceutics & Drug Disposition
Cited by 93

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Background: Rivaroxaban is an oral Factor Xa inhibitor. The primary objective of this communication was to quantitatively predict changes in rivaroxaban exposure when individuals with varying degrees of renal impairment are co‐administered with another drug that is both a P‐gp and a moderate CYP3A4 inhibitor. Methods: A physiologically based pharmacokinetic (PBPK) model was developed to simulate rivaroxaban pharmacokinetics in young (20–45 years) or older (55–65 years) subjects with normal renal function, mild, moderate and severe renal impairment, with or without concomitant use of the combined P‐gp and moderate CYP3A4 inhibitor, erythromycin. Results: The simulations indicate that combined factors (i.e., renal impairment and the use of erythromycin) have a greater impact on rivaroxaban exposure than expected when the impact of these factors are considered individually. Compared with normal young subjects taking rivaroxaban, concurrent mild, moderate or severe renal impairment plus erythromycin resulted in 1.9‐, 2.4‐ or 2.6‐fold increase in exposure, respectively in young subjects; and 2.5‐, 2.9‐ or 3.0‐fold increase in exposure in older subjects. Conclusions: These simulations suggest that a drug–drug–disease interaction is possible, which may significantly increase rivaroxaban exposure and increase bleeding risk. These simulations render more mechanistic insights as to the possible outcomes and allow one to reach a decision to add cautionary language to the approved product labeling for rivaroxaban. Copyright © 2012 John Wiley & Sons, Ltd.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/bdd.1771

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 93

Metadata

Authors
Grillo, J. A., Zhao, P., Bullock, J., Booth, B. P., Lu, M., Robie‐Suh, K., Berglund, E. G., Pang, K. S., Rahman, A., Zhang, L., Lesko, L. J., & Huang, S.
Venue
Biopharmaceutics & Drug Disposition
Publisher
Wiley
Published
2012-03
Volume
33
Issue
2
Pages
99-110
ISSN
  • 0142-2782 (ISSN-L)
  • 1099-081X
OpenAlex
W1500554051
Cited by
93
References
3
FWCI
10.82
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Utility of a physiologically–based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug–drug–disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice. https://app.cochat.ai/papers/10.1002/bdd.1771
The paper
Grillo, J. A., Zhao, P., Bullock, J., Booth, B. P., Lu, M., Robie‐Suh, K., Berglund, E. G., Pang, K. S., Rahman, A., Zhang, L., Lesko, L. J., & Huang, S. (2012). Utility of a physiologically–based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug–drug–disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice. Biopharmaceutics & Drug Disposition. https://doi.org/10.1002/bdd.1771

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.